BioSpace News Archive

Accord Healthcare, having received final FDA approval, is pleased to announce the launch of additional strengths of Hydroxychloroquine Sulfate tablets in dosages of 100mg, 300mg and 400mg.

Bayer announced today the advancement of key innovation projects that showcase the latest in crop protection, seeds & traits and digital solutions.

The NuPET 66 will support research in a wide range of application areas including cancer, neurodegenerative diseases, diabetes, and genetic diseases such as cystic fibrosis, leukodystrophies, and polycystic kidney disease.

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its cash position and revenue for the twelve months ended December 31, 2021 and provided a corporate update.

Aimmune Therapeutics, Inc., a Nestlé Health Science company developing pharmaceutical therapies to prevent, manage, and treat food, gastrointestinal (GI), and metabolic-related diseases, today announced the publication of new clinical data from a pooled analysis of three controlled phase 3 (PALISADE, RAMSES, ARTEMIS) and two open-label extension trials (ARC004, ARC011) of PALFORZIA®

POXEL SA (Euronext: POXEL - FR0012432516), is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to PXL065 for the treatment of patients with adrenomyeloneuropathy (AMN), the most common form of X-linked adrenoleukodystrophy (ALD).

Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, will release its Q1 Fiscal 2022 financial results on Tuesday March 1st, 2022, before markets open.

The report offers detailed overview of the market with recent market dynamics and industrial status.

The global pharma & healthcare market report points out the key trends and developments taking place in this business space in the ongoing COVID-19 times.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced new one-year results from the ongoing Phase 2/3 CAPELLA trial evaluating lenacapavir, the company’s investigational, long-acting HIV-1 capsid inhibitor, in heavily treatment-experienced people living with multi-drug resistant HIV.